RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the US, showed that treatment with the mTOR inhibitor, everolimus, had a significant effect in non-functional neuroendocrine tumours (NETs). There was a statistically significant 52% reduction in the risk of progression or death in favour of everolimus, and also a clinically meaningful 2.8 fold (7.1 months) improvement in median progression-free survival compared with those who had taken placebo.
Presented at the European Cancer Conference (ECC) 2015 by James Yao, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX.
